Probity Advisors Inc. Increases Holdings in Phreesia, Inc. $PHR

Probity Advisors Inc. grew its holdings in shares of Phreesia, Inc. (NYSE:PHR) by 9.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,211 shares of the company’s stock after buying an additional 1,168 shares during the quarter. Probity Advisors Inc.’s holdings in Phreesia were worth $376,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Phreesia by 108.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock valued at $67,606,000 after buying an additional 1,377,904 shares in the last quarter. American Century Companies Inc. raised its position in Phreesia by 3,741.9% in the 1st quarter. American Century Companies Inc. now owns 983,440 shares of the company’s stock worth $25,137,000 after purchasing an additional 957,842 shares during the period. Nuveen LLC purchased a new stake in Phreesia in the 1st quarter worth about $14,206,000. Champlain Investment Partners LLC raised its position in Phreesia by 20.0% in the 1st quarter. Champlain Investment Partners LLC now owns 2,946,489 shares of the company’s stock worth $75,312,000 after purchasing an additional 490,340 shares during the period. Finally, Park West Asset Management LLC raised its position in Phreesia by 111.2% in the 1st quarter. Park West Asset Management LLC now owns 894,501 shares of the company’s stock worth $22,863,000 after purchasing an additional 470,931 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Phreesia Price Performance

Shares of PHR stock opened at $23.11 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.12 and a quick ratio of 2.12. The company has a market capitalization of $1.38 billion, a P/E ratio of -55.02 and a beta of 0.68. The company’s 50-day simple moving average is $25.92 and its two-hundred day simple moving average is $25.97. Phreesia, Inc. has a one year low of $17.07 and a one year high of $32.76.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Thursday, September 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.08. Phreesia had a negative net margin of 5.35% and a negative return on equity of 8.75%. The firm had revenue of $117.26 million for the quarter, compared to the consensus estimate of $116.39 million. During the same period last year, the firm earned ($0.03) earnings per share. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. As a group, equities analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current year.

Insider Buying and Selling at Phreesia

In other news, CFO Balaji Gandhi sold 4,183 shares of the stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $23.28, for a total transaction of $97,380.24. Following the transaction, the chief financial officer directly owned 99,125 shares in the company, valued at approximately $2,307,630. This trade represents a 4.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Linetsky sold 17,445 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $29.73, for a total transaction of $518,639.85. Following the transaction, the insider owned 174,002 shares in the company, valued at approximately $5,173,079.46. This represents a 9.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 92,244 shares of company stock valued at $2,680,720 in the last ninety days. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

PHR has been the topic of a number of recent analyst reports. Mizuho initiated coverage on shares of Phreesia in a research report on Wednesday, August 27th. They issued an “outperform” rating and a $36.00 price objective on the stock. Canaccord Genuity Group increased their price objective on shares of Phreesia from $34.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Phreesia in a research note on Wednesday, October 8th. Piper Sandler upped their target price on shares of Phreesia from $33.00 to $34.00 and gave the stock an “overweight” rating in a research note on Friday, September 5th. Finally, JMP Securities upped their target price on shares of Phreesia from $30.00 to $34.00 and gave the stock a “market outperform” rating in a research note on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Phreesia presently has a consensus rating of “Moderate Buy” and an average price target of $33.85.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.